PMID: 6406900Jun 2, 1983Paper

Variable expression of Ia antigens on the vascular endothelium of mouse skin allografts

Nature
R M de WaalR A Koene

Abstract

Ia antigens are membrane-bound glycoproteins that play a part in antigen recognition and subsequent cell-cell interactions in the immune response. In the mouse they are coded for by the I region of the major histocompatibility complex H-2 and have been demonstrated on B lymphocytes, monocytes, activated T cells, macrophages and dendritic cells, including Langerhans cells. Ia-like antigens have also been detected on the vascular endothelium in man and on epidermal keratinocytes in rats but expression on the latter cells was induced by a graft-versus-host reaction or by contact hypersensitivity. In the mouse, previous studies have suggested that Ia antigens in skin are restricted to epidermal Langerhans cells and it was thought that these were the targets for Ia-dependent rejection of skin allografts. The results presented here show that Ia antigens in mouse allografts are also present on the vascular endothelium but their expression is variable and dependent on the immunological status of the recipient. These findings suggest that vascular endothelial cells can act as targets in Ia-incompatible skin allograft rejection.

References

Nov 1, 1973·The Journal of Clinical Investigation·L W HoyerJ R Hoyer
Apr 1, 1981·In Vitro·P D BowmanG W Goldstein
Nov 1, 1980·The Journal of Experimental Medicine·R M SteinmanI S Mellman
Dec 1, 1980·The Journal of Experimental Medicine·P S SteegJ J Oppenheim
Dec 1, 1980·The Journal of Experimental Medicine·M G ScherE R Unanue
Jul 1, 1981·Clinical Immunology and Immunopathology·P G NataliS Ferrone
Jan 1, 1980·Scandinavian Journal of Immunology·P HäyryL C Andersson

❮ Previous
Next ❯

Citations

Jan 1, 1994·Transplant International : Official Journal of the European Society for Organ Transplantation·I P AlwaynD S Kittur
Jan 1, 1985·Developmental and Comparative Immunology·M F FlajnikL Du Pasquier
Oct 1, 1994·Pharmacology & Therapeutics·F J Burrows, P E Thorpe
Oct 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·F J Burrows, P E Thorpe
Jan 1, 1984·The Journal of Experimental Medicine·J D TylerD Steinmuller
Nov 1, 1987·The Journal of Experimental Medicine·T J RuersG Kootstra
Nov 1, 1987·The Journal of Experimental Medicine·L Mayer, R Shlien
Apr 11, 1992·The Journal of Experimental Medicine·M ZijlstraR Jaenisch
Apr 1, 1996·Journal of Periodontal Research·Y ShimabukuroH Okada
Mar 23, 2004·Annual Review of Immunology·Jaehyuk ChoiJordan S Pober
Apr 29, 2004·BMC Immunology·Annette L RothermelDavid R Johnson
Sep 1, 1984·Blut·H Wekerle, W Fierz
Jan 1, 1995·International Reviews of Immunology·M B Kahaleh
Apr 1, 1989·Kidney International·R A Koene
Nov 1, 1986·Kidney International·P VerroustF Chatelet
Dec 1, 1984·Immunobiology·A K RoskaP E Lipsky
Dec 1, 1984·Immunobiology·D W Mason, A N Barclay
Oct 1, 1985·Immunology Today·M L Rose

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.